Testing TS-172 to Lower Phosphorus in Peritoneal Dialysis Patients
Treatments studied
Part of Hormones & metabolism, Kidney & urinary clinical trials.
This study tests whether a new medicine called TS-172 can help lower phosphorus levels in patients on peritoneal dialysis (a type of kidney treatment). High phosphorus can cause bone problems and other complications, so the trial aims to see if this drug works better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be on peritoneal dialysis (either CAPD or APD) for at least 12 weeks before screening
- You are currently taking at least one phosphate binder (medicine to control phosphorus) with a stable dose for the last 4 weeks
- Your blood phosphorus level is between 3.5 and 7.0 mg/dL at the initial screening visit
- Your phosphorus level increases by at least 1.0 mg/dL during the screening period and reaches 5.5–10.0 mg/dL
- Your parathyroid hormone (PTH) level has not exceeded 500 pg/mL during screening
- You have not had previous surgery or treatment on your parathyroid glands
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called TS-172 for people on dialysis whose phosphorus levels stay high despite taking other phosphorus-lowering drugs. The goal is to see if TS-172 can better control phosphorus and help prevent bone and heart problems that high phosphorus causes.
This trial tests a new medicine, TS-172, to lower high phosphorus levels in people with kidney disease who are on hemodialysis. It looks at safety and effectiveness over a longer period.
This trial tests a new medicine called TS-172 for people with high phosphorus levels who are on hemodialysis. It aims to lower phosphorus levels and is taken along with your current phosphate binder medication.
This trial tests a new drug called AP301 to lower high phosphate levels in people on dialysis. It's designed to help control phosphate, which can be hard to manage with diet and current medications.
This trial compares two treatment goals for blood phosphate levels in people with end-stage kidney disease who are on dialysis. It may help determine which target is safer and works better in real-world care.
This trial tests a new medication called AP306 for people on hemodialysis who have high blood phosphate. It aims to see if the drug is safe, tolerable, and helps lower phosphate levels.
Hear when a new Hyperphosphatemia Patients on Peritoneal Dialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.